Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-16

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)

View source ↗

Summary

FDA approved a supplemental application for a generic buprenorphine and naloxone product from Lannett Company, expanding access to treatment for opioid use diso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)